Aldeyra Therapeutics, Inc to Post FY2027 Earnings of $0.22 Per Share, HC Wainwright Forecasts (NASDAQ:ALDX)

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) – Equities researchers at HC Wainwright raised their FY2027 earnings per share estimates for Aldeyra Therapeutics in a report released on Monday, May 6th. HC Wainwright analyst M. Caufield now forecasts that the biotechnology company will post earnings per share of $0.22 for the year, up from their prior estimate of $0.16. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.14) per share. HC Wainwright also issued estimates for Aldeyra Therapeutics’ FY2028 earnings at $0.62 EPS.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings results on Thursday, March 7th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.13.

Other analysts have also recently issued research reports about the company. StockNews.com cut Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday. Oppenheimer reaffirmed an “outperform” rating and issued a $10.00 price objective on shares of Aldeyra Therapeutics in a report on Monday.

Aldeyra Therapeutics Price Performance

Aldeyra Therapeutics stock opened at $4.07 on Wednesday. Aldeyra Therapeutics has a 1-year low of $1.42 and a 1-year high of $11.97. The stock has a market cap of $241.81 million, a PE ratio of -7.98 and a beta of 1.45. The stock’s fifty day moving average is $3.72 and its two-hundred day moving average is $3.24.

Institutional Trading of Aldeyra Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in ALDX. BNP Paribas Financial Markets boosted its position in Aldeyra Therapeutics by 23.4% during the 1st quarter. BNP Paribas Financial Markets now owns 25,278 shares of the biotechnology company’s stock worth $83,000 after purchasing an additional 4,797 shares during the period. Denali Advisors LLC bought a new position in shares of Aldeyra Therapeutics during the first quarter worth about $155,000. Kingswood Wealth Advisors LLC bought a new position in shares of Aldeyra Therapeutics during the first quarter worth about $49,000. Woodstock Corp raised its stake in Aldeyra Therapeutics by 46.3% during the first quarter. Woodstock Corp now owns 170,715 shares of the biotechnology company’s stock worth $558,000 after acquiring an additional 54,011 shares during the period. Finally, Los Angeles Capital Management LLC raised its stake in Aldeyra Therapeutics by 240.9% during the first quarter. Los Angeles Capital Management LLC now owns 380,773 shares of the biotechnology company’s stock worth $1,245,000 after acquiring an additional 269,061 shares during the period. 59.71% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Aldeyra Therapeutics

In related news, insider Bruce Greenberg sold 13,201 shares of Aldeyra Therapeutics stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $3.41, for a total transaction of $45,015.41. Following the completion of the transaction, the insider now directly owns 120,699 shares in the company, valued at approximately $411,583.59. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Aldeyra Therapeutics news, CEO Todd C. Brady sold 97,914 shares of the business’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $3.27, for a total value of $320,178.78. Following the completion of the transaction, the chief executive officer now directly owns 1,556,622 shares in the company, valued at approximately $5,090,153.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Bruce Greenberg sold 13,201 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $3.41, for a total value of $45,015.41. Following the sale, the insider now owns 120,699 shares of the company’s stock, valued at $411,583.59. The disclosure for this sale can be found here. Insiders have bought 355,933 shares of company stock valued at $1,473,245 in the last quarter. 7.30% of the stock is currently owned by corporate insiders.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-?B, inflammasomes, and Scavenger Receptor A.